Title: European Medicines Agency Investigating Potential Link between GLP-1 Receptor Agonists and Suicidal Thoughts
In a recent development, the European Medicines Agency (EMA) has revealed that its Committee for Safety is currently reviewing data concerning the risk of suicidal thoughts and thoughts of self-harm associated with GLP-1 receptor agonists. These medications are commonly used for weight loss as well as the treatment of type 2 diabetes.
While issuing a note urging caution, the EMA highlighted that it is yet to ascertain whether the reported cases of such thoughts are directly linked to the medications themselves, the underlying conditions of the patients, or other factors.
This review was initiated by the Icelandic drug agency, prompted by reports of suicidal thoughts and self-harm in individuals using liraglutide and semaglutide-based drugs. As part of the analysis, approximately 150 reports have been retrieved and subjected to thorough examination.
Providing further insight, the EMA explained that liraglutide and semaglutide are widely used medications, with more than 20 million patients being exposed to these drugs annually. The specific products under investigation are marketed under the names of Saxenda, Wegovy, and Ozempic.
According to the EMA, Saxenda and Wegovy are authorized for weight management in obese or overweight individuals. On the other hand, Ozempic is approved for the treatment of adults with insufficiently controlled type 2 diabetes but has been used off-label for weight loss purposes.
At present, no restrictions have been imposed on the prescription and utilization of these products. The EMA clarified that the presence of a signal does not necessarily imply that a medicine is responsible for the reported adverse events.
Nevertheless, the regulatory agency has recommended that both patients and healthcare providers adhere to the approved product information when using GLP-1 receptor agonists. Additionally, they are encouraged to promptly report any suspected side effects to the relevant authorities.
The conclusions of this investigation are anticipated to be announced by November of this year.
To read the full article, visit ANSA.it.